Back

Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Chronic heart failure - Pharmacotherapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Michael Boehm

Saarland University Hospital, Homburg (Germany)

4 More presentations in this session

Presentation thumbnail
Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study
Associate Professor G. Savarese (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Direct effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial
Doctor C. Andersen (Herlev, DK)
Abstract Slides
Presentation thumbnail
Acute effect of empagliflozin on serum uric acid - a subanalysis of the EMPAG-HF trial (effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure)
Mr J. Bogoviku (Jena, DE)
Abstract Slides
Presentation thumbnail
Real-world eligibility and cost-effectiveness analysis for empagliflozin in patients with heart failure
Doctor E. Kim (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - Pharmacotherapy

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources